Systemic sclerosis pulmonary
RecruitingStudy of rituximab and mycophenolate mofetil combination therapy compared to placebo for patients with interstitial lung disease related to systemic sclerosis
Study of rituximab and mycophenolate mofetil combination therapy compared to placebo for patients with interstitial lung disease related to systemic sclerosis
- Disease:Systemic sclerosis pulmonary
- Substances:RituximabMycophenolate Mofetil
France- Participants:18–64 years · 65+ years
- Substances:Rituximab
- Sponsor:Centre Hospitalier Regional Universitaire De Tours




